191171-49-0

Usage

Chemical structure

A urea derivative with a boronic ester on the benzene ring.

Usage

In organic synthesis and catalysis as a ligand for metal-mediated reactions.

Role in the Suzuki-Miyaura coupling reaction

Facilitates carbon-carbon bond formation in organic chemistry.

Participation in cross-coupling reactions

The boronic ester functionality allows it to react with aryl halides or triflates.

Use in the preparation of pharmaceuticals and agrochemicals

It is used in the production of various medications and chemicals used in agriculture.

Upstream product

• 32315-10-9 bis(trichloromethyl) carbonate 
• 74-89-5 methylamine 
• 210907-84-9 3-aminophenylboronic acid pinacolate 
• 591-19-5 m-Bromoaniline 
• 25216-72-2 3-bromophenyl carbamic acid methyl ester 
• 20940-44-7 N-(3-bromo-phenyl)-N'-methyl-urea 
• 73183-34-3 bis(pinacol)diborane 
• 787591-43-9 2-(3-isocyanatophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 

Downstream Products

• 1204594-59-1 4-(1-methyl-6-(3-(3-methylureido)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)benzamide 
• 1395786-74-9 methyl 3-[3-(3-{[(methylamino)carbonyl]amino}phenyl)imidazo[1,2-b]pyridazin-7-yl]benzoate 
• 1383481-30-8 3-[3-(3-{[(methylamino)carbonyl]amino}phenyl)imidazo[1,2-b]pyridazin-7-yl]benzoic acid 

Relevant academic research and scientific papers

COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF

Disclosed are a class of coumarin-like cyclic compounds as MEK inhibitors and pharmaceutical compositions comprising the compounds, and the use of same in the preparation of a drug for treating MEK-related diseases. Particularly disclosed are compounds as shown in formula (I) and pharmaceutically acceptable salts thereof or tautomers thereof.

SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3

The present invention relates to substituted imidazopyridazines and substituted benzimidazoles, as well as pharmaceutical compositions comprising the same, which are FGFR3 inhibitors useful in the treatment of cancer and other diseases.

COMPOUNDS FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

Compounds of formula (I): wherein R1, R2, R3, L1, L2, and Y are as defined herein, are useful for the treatment or prophylaxis of conditions such as Duchenne muscular dystrophy, Becker muscular dystrophy, and cachexia.

4-PHENOXY-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDINE AND N-ARYL-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES

The invention relates to 4,6-disubstituted-1H-pyrazolo[3,4-d]pyrimidin-4-amine compounds, including 4-phenoxy-6-aryl-1H-pyrazolo[3,4-d]pyrimidine and N-aryl-6-aryl-1H-pyrazolo[3,4-d]pyrimidin-4-amine compounds of the Formula I: or a pharmaceutically accep